Ureidopeptide GLP-1 analogues with prolonged activity


Journal

Chemical science
ISSN: 2041-6520
Titre abrégé: Chem Sci
Pays: England
ID NLM: 101545951

Informations de publication

Date de publication:
14 Nov 2019
Historique:
received: 26 04 2019
accepted: 27 08 2019
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 6 2 2020
Statut: epublish

Résumé

The high demand of the pharmaceutical industry for new modalities to address the diversification of biological targets with large surfaces of interaction led us to investigate the replacement of α-amino acid residues with ureido units at selected positions in peptides to improve potency and generate effective incretin mimics. Based on molecular dynamics simulations, N-terminally modified GLP-1 analogues with a ureido residue replacement at position 2 were synthesized and showed preservation of agonist activity while exhibiting a substantial increase in stability. This enabling platform was applied to exenatide and lixisenatide analogues to generate two new ureidopeptides with antidiabetic properties and longer duration of action. Further analyses demonstrated that the improvement was due mainly to differences in signal bias and trafficking of the GLP-1 receptor. This study demonstrates the efficacy of single α-amino acid substitution with ureido residues to design long lasting peptides.

Identifiants

pubmed: 32015811
doi: 10.1039/c9sc02079a
pii: c9sc02079a
pmc: PMC6977461
doi:

Types de publication

Journal Article

Langues

eng

Pagination

9872-9879

Subventions

Organisme : Medical Research Council
ID : MR/K023667/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010676/1
Pays : United Kingdom

Informations de copyright

This journal is © The Royal Society of Chemistry 2019.

Références

Trends Pharmacol Sci. 2019 Feb;40(2):87-91
pubmed: 30606501
Angew Chem Int Ed Engl. 2017 Aug 21;56(35):10294-10323
pubmed: 28186380
Regul Pept. 2007 Jun 7;141(1-3):113-9
pubmed: 17292977
ACS Chem Neurosci. 2012 Mar 21;3(3):193-203
pubmed: 22860188
J Med Chem. 2017 Nov 9;60(21):8816-8833
pubmed: 29064243
Biochem J. 2016 Sep 15;473(18):2881-91
pubmed: 27422784
Angew Chem Int Ed Engl. 2003 Jan 13;42(2):202-5
pubmed: 12532350
Bioorg Med Chem. 2016 Mar 15;24(6):1163-70
pubmed: 26895657
J Am Chem Soc. 2015 Oct 7;137(39):12422-5
pubmed: 26368649
J Med Chem. 2010 Sep 9;53(17):6412-20
pubmed: 20687610
Nature. 2017 Jun 8;546(7657):248-253
pubmed: 28538729
Acc Chem Res. 2017 Jul 18;50(7):1541-1556
pubmed: 28598597
Curr Opin Struct Biol. 2016 Aug;39:96-105
pubmed: 27390896
Nat Commun. 2018 Apr 23;9(1):1602
pubmed: 29686402
Nat Commun. 2019 Feb 25;10(1):924
pubmed: 30804332
Nat Commun. 2015 Dec 01;6:8918
pubmed: 26621478
Bioorg Med Chem. 2018 Jun 1;26(10):2759-2765
pubmed: 29395804
PLoS One. 2015 Feb 27;10(2):e0116805
pubmed: 25723538
Nature. 2018 Mar 1;555(7694):121-125
pubmed: 29466332
Endocrinology. 2012 Dec;153(12):5735-45
pubmed: 23033273
J Am Chem Soc. 2016 Nov 16;138(45):14970-14979
pubmed: 27813409
Pharmacol Rev. 2016 Oct;68(4):954-1013
pubmed: 27630114
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
J Med Chem. 2008 Nov 27;51(22):7303-7
pubmed: 18950150
Methods Enzymol. 2013;523:407-29
pubmed: 23422441
J Med Chem. 2016 Sep 22;59(18):8221-32
pubmed: 27529632
Org Lett. 2012 Jun 15;14(12):3130-3
pubmed: 22642718
J Am Chem Soc. 2017 Nov 22;139(46):16688-16695
pubmed: 29130686
ChemMedChem. 2018 Apr 6;13(7):662-671
pubmed: 29430842

Auteurs

Juliette Fremaux (J)

UREkA - ImmuPharma Group , 2 rue Robert Escarpit , 33607 Pessac , France . Email: sebastien.goudreau@immupharma.com.

Claire Venin (C)

UREkA - ImmuPharma Group , 2 rue Robert Escarpit , 33607 Pessac , France . Email: sebastien.goudreau@immupharma.com.

Laura Mauran (L)

UREkA - ImmuPharma Group , 2 rue Robert Escarpit , 33607 Pessac , France . Email: sebastien.goudreau@immupharma.com.

Robert Zimmer (R)

UREkA - ImmuPharma Group , 2 rue Robert Escarpit , 33607 Pessac , France . Email: sebastien.goudreau@immupharma.com.

Florian Koensgen (F)

Laboratoire d'Innovation Thérapeutique , UMR7200 CNRS-Université de Strasbourg , 74 route du Rhin , 67400 Illkirch , France.

Didier Rognan (D)

Laboratoire d'Innovation Thérapeutique , UMR7200 CNRS-Université de Strasbourg , 74 route du Rhin , 67400 Illkirch , France.

Stavroula Bitsi (S)

Section of Cell Biology and Functional Genomics , Imperial College London , London W12 0NN , UK.

Maria A Lucey (MA)

Section of Investigative Medicine , Imperial College London , London W12 0NN , UK.

Ben Jones (B)

Section of Investigative Medicine , Imperial College London , London W12 0NN , UK.

Alejandra Tomas (A)

Section of Cell Biology and Functional Genomics , Imperial College London , London W12 0NN , UK.

Gilles Guichard (G)

Univ. Bordeaux , CNRS , CBMN , UMR 5248 , Institut Européen de Chimie et Biologie , 2 rue Robert Escarpit , 33607 Pessac , France . Email: g.guichard@iecb.u-bordeaux.fr.

Sébastien R Goudreau (SR)

UREkA - ImmuPharma Group , 2 rue Robert Escarpit , 33607 Pessac , France . Email: sebastien.goudreau@immupharma.com.

Classifications MeSH